Inflammatory bowel disease

被引:0
作者
Herrlinger, K [1 ]
Stange, EF [1 ]
机构
[1] Robert Bosch Krankenhaus, D-70376 Stuttgart, Germany
来源
INTERNIST | 2003年 / 44卷 / 09期
关键词
inflammatory bowel disease; Crohn's disease; ulcerative colitis; immunosuppression; infliximab;
D O I
10.1007/s00108-003-1008-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The etiology of inflammatory bowel diseases is still unknown. However, there seems to be a primary defect in mucosal barrier function resulting in a chronic inflammatory process. Both entities, Crohn's disease and ulcerative colitis show characteristic differences in clinical presentation and laboratory, radiological as well as endoscopical criteria. In some cases of the so called indeterminate colitis a clear distinction may not be possible. Therapy of inflammatory bowel disease aims for a suppression of the mucosal inflammation. Site, extent and especially the course of disease are crucial for the decision when and how to treat the patient. According to the patient's symptoms and disease history topical or systemic application of mesalazine or corticosteroids are used. In case of an intermittent course of disease treatment of the single flare should be started whereas in chronic active disease an immunosuppression with azathioprine, methotrexate or in therapy refractory cases infliximab is warranted.
引用
收藏
页码:1151 / 1171
页数:21
相关论文
共 32 条
[1]   Defensins and innate host defence of the gastrointestinal tract [J].
Bevins, CL ;
Martin-Porter, E ;
Ganz, T .
GUT, 1999, 45 (06) :911-915
[2]   The genetics of inflammatory bowel disease [J].
Bonen, DK ;
Cho, JH .
GASTROENTEROLOGY, 2003, 124 (02) :521-536
[3]   Mesalamine in the maintenance treatment of Crohn's disease: A meta-analysis adjusted for confounding variables [J].
Camma, C ;
Giunta, M ;
Rosselli, M ;
Cottone, M .
GASTROENTEROLOGY, 1997, 113 (05) :1465-1473
[4]   An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy [J].
Dubinsky, MC ;
Hassard, PV ;
Seidman, EG ;
Kam, LY ;
Abreu, MT ;
Targan, SR ;
Vasiliauskas, EA .
INFLAMMATORY BOWEL DISEASES, 2001, 7 (03) :181-189
[5]   A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease [J].
Feagan, BG ;
Fedorak, RN ;
Irvine, EJ ;
Wild, G ;
Sutherland, L ;
Steinhart, AH ;
Greenberg, GR ;
Koval, J ;
Wong, CJ ;
Hopkins, M ;
Hanauer, SB ;
McDonald, JWD .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (22) :1627-1632
[6]   METHOTREXATE FOR THE TREATMENT OF CROHNS-DISEASE [J].
FEAGAN, BG ;
ROCHON, J ;
FEDORAK, RN ;
IRVINE, EJ ;
WILD, G ;
SUTHERLAND, L ;
STEINHART, AH ;
GREENBERG, GR ;
GILLIES, R ;
HOPKINS, M ;
HANAUER, SB ;
MCDONALD, JWD .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (05) :292-297
[7]   Crohn's disease: a defensin deficiency syndrome? [J].
Fellermann, K ;
Wehkamp, J ;
Herrlinger, KR ;
Stange, EF .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2003, 15 (06) :627-634
[8]   Response of refractory colitis to intravenous or oral tacrolimus (FK506) [J].
Fellermann, K ;
Tanko, T ;
Herrlinger, KR ;
Witthoeft, T ;
Homann, N ;
Bruening, A ;
Ludwig, D ;
Stange, EF .
INFLAMMATORY BOWEL DISEASES, 2002, 8 (05) :317-324
[9]   A simple classification of Crohn's disease: Report of the Working Party for the world congresses of gastroenterology, Vienna 1998 [J].
Gasche, C ;
Scholmerich, J ;
Brynskov, J ;
D'Haens, G ;
Hanauer, SB ;
Irvine, EJ ;
Jewell, DP ;
Rachmilewitz, D ;
Sachar, DB ;
Sandborn, WJ ;
Sutherland, LR .
INFLAMMATORY BOWEL DISEASES, 2000, 6 (01) :8-15
[10]   Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial [J].
Hanauer, SB ;
Feagan, BG ;
Lichtenstein, GR ;
Mayer, LF ;
Schreiber, S ;
Colombel, JF ;
Rachmilewitz, D ;
Wolf, DC ;
Olson, A ;
Bao, WH ;
Rutgeerts, P .
LANCET, 2002, 359 (9317) :1541-1549